Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) was approved in April of 2025. The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features PSMA-SIR-T™, a potentially first-in-class engineered T-cell therapy targeting Prostate-Specific Membrane Antigen (PSMA), engineered to overcome the core failures of cell therapies in solid tumors.
